BridgeBio Pharma, Inc. (BBIO) has 20 SEC Form 4 insider filings on record in the last 90 days. No insider purchases were filed — 2 sales totalling $3.9M. Most recent filing: Aug. 20, 2026.
| Date | Insider | Value | Shares | Stake | Pre-planned | Links |
|---|---|---|---|---|---|---|
| Aug. 20, 2026 filed Aug. 18, 2026 | Kumar Neil Chief Executive Officer | −$3,727,251 | 44,980 | −8% | Yes | |
|
|
||||||
| Aug. 18, 2026 filed Aug. 16, 2026 | Apuli Maricel Chief Accounting Officer | $376,460 | 4,714 | −4% | No | |
|
|
||||||
| Aug. 18, 2026 filed Aug. 16, 2026 | Kumar Neil Chief Executive Officer | — | +34,980 | +62% | No | |
|
|
||||||
| Aug. 18, 2026 filed Aug. 16, 2026 | Trimarchi Thomas President and CFO | $1,819,291 | 22,781 | −6% | No | |
|
|
||||||
| Aug. 3, 2026 filed July 30, 2026 | Apuli Maricel Chief Accounting Officer | −$160,120 | 2,000 | −2% | Yes | |
|
|
||||||
Showing the 5 most recent of 20 filings in the last 90 days.
Form 4 is the filing company officers, directors and 10% shareholders must submit to the SEC within two business days of trading their own company's stock. Open-market purchases generally carry more signal than sales, which are often scheduled in advance. More on how this works.
Real-time Telegram alerts the moment a Form 4 is filed. Filings shown here are delayed by 72 hours.
Start free